Ovation Science Inc. Closes Private Placement
Vancouver, BC, Las Vegas, NV – October 18th, 2023 (CSE: OVAT and OTC: OVATF) – Ovation Science Inc. (“Ovation” or the “Company”) announces that there was an error in its news release dated October 12, 2023.
The Company issued 4,000,000 Units at a price of $0.05 per unit for gross proceeds of $200,000. Net $184,000 after payment of commissions totaling $16,000. The Company issued a total of 480,000 brokers warrants exercisable to purchase one common share at $0.05 per share for 24 months from closing to registered
investment dealers in connection with the offering. Each unit consists of one common share of the Company and one non-transferable share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of $0.05 per share for a period of 24 months from closing of the private placement.
In the news release October 12, 2023, the Company erroneously announced that they had issued 2,000,000 Units at a price of $0.05 per unit for gross proceeds of $200,000.
About Ovation Science Inc.
Ovation Science is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation’s own brands; Arlo CBD Beauty and InVibe MD — all powered by its patented Invisicare skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation’s management and science team have created a unique pipeline of over 30 proprietary medical/wellness topical and transdermal products along with a line of anti-aging/beauty formulas. Ovation earns revenues from royalties on licensees’ sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada, and Las Vegas, United States.
Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
FOR CORPORATE INQUIRIES:
Doreen McMorran
doreen@ovationscience.com
Phone: 702.588.4646